Cargando…
Global eligibility and cost effectiveness of icosapent ethyl in primary and secondary cardiovascular prevention
Icosapent ethyl (IPE) is a purified eicosapentaenoic acid–only omega-3 fatty acid that significantly reduced cardiovascular (CV) events in patients receiving statins with established cardiovascular disease (CVD) and those with diabetes and additional risk factors in the pivotal REDUCE-IT trial. Sinc...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10501481/ https://www.ncbi.nlm.nih.gov/pubmed/37719970 http://dx.doi.org/10.3389/fcvm.2023.1220017 |
_version_ | 1785106119842070528 |
---|---|
author | Toth, Peter P. Ferrières, Jean Waters, Max Mortensen, Martin Bødtker Lan, Nick S. R. Wong, Nathan D. |
author_facet | Toth, Peter P. Ferrières, Jean Waters, Max Mortensen, Martin Bødtker Lan, Nick S. R. Wong, Nathan D. |
author_sort | Toth, Peter P. |
collection | PubMed |
description | Icosapent ethyl (IPE) is a purified eicosapentaenoic acid–only omega-3 fatty acid that significantly reduced cardiovascular (CV) events in patients receiving statins with established cardiovascular disease (CVD) and those with diabetes and additional risk factors in the pivotal REDUCE-IT trial. Since the publication of REDUCE-IT, there has been global interest in determining IPE eligibility in different patient populations, the proportion of patients who may benefit from IPE, and cost effectiveness of IPE in primary and secondary prevention settings. The aim of this review is to summarize information from eligibility and cost effectiveness studies of IPE to date. A total of sixteen studies were reviewed, involving 2,068,111 patients in the primary or secondary prevention settings worldwide. Up to forty-five percent of patients were eligible for IPE, depending on the selection criteria used (ie, REDUCE-IT criteria, US Food and Drug Administration label, Health Canada label, practice guidelines) and the population studied. Overall, eight cost-effectiveness studies across the United States, Canada, Germany, Israel, and Australia were included in this review and findings indicated that IPE is particularly cost effective in patients with established CVD. |
format | Online Article Text |
id | pubmed-10501481 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-105014812023-09-15 Global eligibility and cost effectiveness of icosapent ethyl in primary and secondary cardiovascular prevention Toth, Peter P. Ferrières, Jean Waters, Max Mortensen, Martin Bødtker Lan, Nick S. R. Wong, Nathan D. Front Cardiovasc Med Cardiovascular Medicine Icosapent ethyl (IPE) is a purified eicosapentaenoic acid–only omega-3 fatty acid that significantly reduced cardiovascular (CV) events in patients receiving statins with established cardiovascular disease (CVD) and those with diabetes and additional risk factors in the pivotal REDUCE-IT trial. Since the publication of REDUCE-IT, there has been global interest in determining IPE eligibility in different patient populations, the proportion of patients who may benefit from IPE, and cost effectiveness of IPE in primary and secondary prevention settings. The aim of this review is to summarize information from eligibility and cost effectiveness studies of IPE to date. A total of sixteen studies were reviewed, involving 2,068,111 patients in the primary or secondary prevention settings worldwide. Up to forty-five percent of patients were eligible for IPE, depending on the selection criteria used (ie, REDUCE-IT criteria, US Food and Drug Administration label, Health Canada label, practice guidelines) and the population studied. Overall, eight cost-effectiveness studies across the United States, Canada, Germany, Israel, and Australia were included in this review and findings indicated that IPE is particularly cost effective in patients with established CVD. Frontiers Media S.A. 2023-08-31 /pmc/articles/PMC10501481/ /pubmed/37719970 http://dx.doi.org/10.3389/fcvm.2023.1220017 Text en © 2023 Toth, Ferrières, Waters, Mortensen, Lan and Wong. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) (https://creativecommons.org/licenses/by/4.0/) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Cardiovascular Medicine Toth, Peter P. Ferrières, Jean Waters, Max Mortensen, Martin Bødtker Lan, Nick S. R. Wong, Nathan D. Global eligibility and cost effectiveness of icosapent ethyl in primary and secondary cardiovascular prevention |
title | Global eligibility and cost effectiveness of icosapent ethyl in primary and secondary cardiovascular prevention |
title_full | Global eligibility and cost effectiveness of icosapent ethyl in primary and secondary cardiovascular prevention |
title_fullStr | Global eligibility and cost effectiveness of icosapent ethyl in primary and secondary cardiovascular prevention |
title_full_unstemmed | Global eligibility and cost effectiveness of icosapent ethyl in primary and secondary cardiovascular prevention |
title_short | Global eligibility and cost effectiveness of icosapent ethyl in primary and secondary cardiovascular prevention |
title_sort | global eligibility and cost effectiveness of icosapent ethyl in primary and secondary cardiovascular prevention |
topic | Cardiovascular Medicine |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10501481/ https://www.ncbi.nlm.nih.gov/pubmed/37719970 http://dx.doi.org/10.3389/fcvm.2023.1220017 |
work_keys_str_mv | AT tothpeterp globaleligibilityandcosteffectivenessoficosapentethylinprimaryandsecondarycardiovascularprevention AT ferrieresjean globaleligibilityandcosteffectivenessoficosapentethylinprimaryandsecondarycardiovascularprevention AT watersmax globaleligibilityandcosteffectivenessoficosapentethylinprimaryandsecondarycardiovascularprevention AT mortensenmartinbødtker globaleligibilityandcosteffectivenessoficosapentethylinprimaryandsecondarycardiovascularprevention AT lannicksr globaleligibilityandcosteffectivenessoficosapentethylinprimaryandsecondarycardiovascularprevention AT wongnathand globaleligibilityandcosteffectivenessoficosapentethylinprimaryandsecondarycardiovascularprevention |